Short answer
Maze Therapeutics, Inc. (MAZE) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board additions: Paula A. Johnson and Sophie Kornowski appointed as Class III and Class I directors, respectively.
Maze Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board additions: Paula A. Johnson and Sophie Kornowski appointed as Class III and Class I directors, respectively
- Dr. Kornowski joins audit and compensation committees, strengthening biopharma, investment and business-development expertise
- Dr. Johnson joins nominating and corporate governance committee, adding academic medicine and public-health leadership
- Each director receives pro rata $40,000 annual cash retainer plus committee retainers and options for 36,000 shares
- Board class realignment changes Nancy Andrews to Class II and Hervé Hoppenot to Class III without reducing board continuity
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD, not treated as filed under Exchange Act Section 18
- Exhibit excluded from Securities Act Sections 11 and 12(a)(2) liability
- Exhibit not incorporated by reference into other SEC filings unless expressly stated
Item EX-99.1 · Exhibit EX-99.1
- Paula Johnson and Sophie Kornowski appointed to Maze’s Board, strengthening clinical, biopharmaceutical, partnering, and M&A expertise
- MZE829 additional AMKD data expected in late 2026 or early 2027
- Initial MZE782 data expected in 2027, with additional trial initiations for both molecules next year
- Board expansion supports Maze’s transition toward late-stage clinical development and pre-commercial planning
- Pipeline execution remains dependent on clinical results, regulatory approvals, and funding availability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Maze Therapeutics, Inc. 8-K filings
Get the next MAZE 8-K as it lands
Follow MAZE for push alerts, or ask the research agent what this filing means.